RAPPRapport Therapeutics, Inc.

$52.44

The financials

Rapport Therapeutics, Inc. by the numbers

Rapport Therapeutics, Inc. (RAPP) reported revenue of $0 in Q2 2026 (quarter ended June 30, 2026). That came with net loss of $57M.

Rapport Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$0$0n/a
Operating income−$61M−$29Mn/a
Net income−$57M−$27Mn/a
Diluted EPS−$1.19−$0.75n/a